KR101998000B1 - 신규한 화합물 - Google Patents

신규한 화합물 Download PDF

Info

Publication number
KR101998000B1
KR101998000B1 KR1020177007738A KR20177007738A KR101998000B1 KR 101998000 B1 KR101998000 B1 KR 101998000B1 KR 1020177007738 A KR1020177007738 A KR 1020177007738A KR 20177007738 A KR20177007738 A KR 20177007738A KR 101998000 B1 KR101998000 B1 KR 101998000B1
Authority
KR
South Korea
Prior art keywords
compound
formula
fluoro
tetrahydro
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177007738A
Other languages
English (en)
Korean (ko)
Other versions
KR20170055489A (ko
Inventor
니알 앤드류 앤더슨
매튜 하워드 제임스 캠벨-크라우포드
애슐리 폴 한코크
존 마틴 프리차드
조안나 메리 레드몬드
Original Assignee
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 filed Critical 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Publication of KR20170055489A publication Critical patent/KR20170055489A/ko
Application granted granted Critical
Publication of KR101998000B1 publication Critical patent/KR101998000B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177007738A 2014-09-26 2015-09-22 신규한 화합물 Expired - Fee Related KR101998000B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1417002.1 2014-09-26
GBGB1417002.1A GB201417002D0 (en) 2014-09-26 2014-09-26 Novel compound
PCT/EP2015/071776 WO2016046225A1 (en) 2014-09-26 2015-09-22 Novel compounds

Publications (2)

Publication Number Publication Date
KR20170055489A KR20170055489A (ko) 2017-05-19
KR101998000B1 true KR101998000B1 (ko) 2019-07-08

Family

ID=51901158

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177007738A Expired - Fee Related KR101998000B1 (ko) 2014-09-26 2015-09-22 신규한 화합물

Country Status (37)

Country Link
US (3) US9956209B2 (enExample)
EP (2) EP3428167A1 (enExample)
JP (1) JP6611799B2 (enExample)
KR (1) KR101998000B1 (enExample)
CN (1) CN107074848B (enExample)
AR (1) AR101994A1 (enExample)
AU (1) AU2015320858B2 (enExample)
BR (1) BR112017006251A2 (enExample)
CA (1) CA2962315A1 (enExample)
CL (1) CL2017000705A1 (enExample)
CO (1) CO2017002714A2 (enExample)
CR (1) CR20170112A (enExample)
CY (1) CY1121071T1 (enExample)
DK (1) DK3197892T3 (enExample)
DO (1) DOP2017000081A (enExample)
EA (1) EA031481B1 (enExample)
ES (1) ES2690748T3 (enExample)
GB (1) GB201417002D0 (enExample)
HR (1) HRP20181796T1 (enExample)
HU (1) HUE041827T2 (enExample)
IL (1) IL250592A0 (enExample)
JO (1) JO3413B1 (enExample)
LT (1) LT3197892T (enExample)
MA (1) MA40580B1 (enExample)
MX (1) MX2017003948A (enExample)
PE (1) PE20170502A1 (enExample)
PH (1) PH12017500361A1 (enExample)
PL (1) PL3197892T3 (enExample)
PT (1) PT3197892T (enExample)
RS (1) RS58000B1 (enExample)
SG (1) SG11201701183YA (enExample)
SI (1) SI3197892T1 (enExample)
SM (1) SMT201800513T1 (enExample)
TW (1) TW201629056A (enExample)
UA (1) UA119181C2 (enExample)
UY (1) UY36314A (enExample)
WO (1) WO2016046225A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604589D0 (en) * 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
JP7220653B2 (ja) * 2016-11-08 2023-02-10 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのピロールアミド
MA46745A (fr) 2016-11-08 2021-03-31 Bristol Myers Squibb Co Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
BR112019009245A2 (pt) 2016-11-08 2019-07-16 Bristol-Myers Squibb Company azol amidas e aminas como inibidores de alfav integrina
PL3538525T3 (pl) 2016-11-08 2022-09-12 Bristol-Myers Squibb Company 3-podstawione kwasy propionowe jako inhibitory integryny alfa v
BR112019009129A2 (pt) 2016-11-08 2019-07-16 Bristol-Myers Squibb Company compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
CN116283977A (zh) 2017-02-28 2023-06-23 莫菲克医疗股份有限公司 αvβ6整合蛋白的抑制剂
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
WO2018167295A1 (en) * 2017-03-17 2018-09-20 Technische Universität München LIGANDS FOR INTEGRIN αvβ8, SYNTHESIS AND USES THEREOF
AU2018365793A1 (en) 2017-11-07 2020-06-18 Bristol-Myers Squibb Company Pyrrolopyrazine derivatives as alpha V integrin inhibitors
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用
ES3027421T3 (en) * 2018-08-29 2025-06-13 Morphic Therapeutic Inc Inhibitors of (alpha-v)(beta-6) integrin
SG11202101913PA (en) * 2018-08-29 2021-03-30 Morphic Therapeutic Inc INHIBITING aV ß6 INTEGRIN
EP3843727A4 (en) * 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
TWI857918B (zh) * 2018-08-29 2024-10-01 美商莫菲克醫療股份有限公司 αvβ6整合素之抑制劑
US12351634B2 (en) * 2018-10-09 2025-07-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cilengitide for ameliorating cardiac fibrosis occurring in response to myocardial infarction
US11034710B2 (en) * 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024797A1 (en) 1999-10-04 2001-04-12 Merck & Co., Inc. Integrin receptor antagonists
WO2005082889A1 (en) 2004-02-18 2005-09-09 Janssen Pharmaceutica N.V. Piperidinyl targeting compounds that selectively bind integrins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100397A3 (en) 1997-12-17 2002-10-28 Merck & Co Inc Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation
JP2002508323A (ja) 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
AU749351B2 (en) 1999-06-02 2002-06-27 Merck & Co., Inc. Alpha V integrin receptor antagonists
AU748949B2 (en) 1999-06-23 2002-06-13 Merck & Co., Inc. Integrin receptor antagonists
ATE245645T1 (de) 1999-11-08 2003-08-15 Merck & Co Inc Verfahren und zwischenprodukte zur herstellung von imidazolinon alpha v integrin antagonisten
US6921767B2 (en) 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
WO2001096334A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
DE60126496T2 (de) 2000-07-26 2007-11-15 Merck & Co., Inc. Alpha v integrin-rezeptor-antagonisten
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
CA2432504A1 (en) 2001-01-03 2002-07-11 Merck & Co., Inc. Methods and compositions for treating periodontal disease
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
EP2336185A1 (en) 2002-03-13 2011-06-22 Biogen Idec Inc. Anti- alpha v beta 6 antibodies
WO2004058254A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
US7705018B2 (en) 2007-03-23 2010-04-27 Amgen Inc. Substituted quinolines and their uses in treatment of inflammatory and related conditions
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
WO2009055418A1 (en) 2007-10-22 2009-04-30 Smithkline Beecham Corporation Pyridosulfonamide derivatives as pi3 kinase inhibitors
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2976634C (en) 2015-02-19 2023-10-17 Scifluor Life Sciences, Inc Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
WO2016145258A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024797A1 (en) 1999-10-04 2001-04-12 Merck & Co., Inc. Integrin receptor antagonists
WO2005082889A1 (en) 2004-02-18 2005-09-09 Janssen Pharmaceutica N.V. Piperidinyl targeting compounds that selectively bind integrins

Also Published As

Publication number Publication date
CL2017000705A1 (es) 2017-11-03
US20190275016A1 (en) 2019-09-12
CA2962315A1 (en) 2016-03-31
UY36314A (es) 2016-04-29
DOP2017000081A (es) 2017-04-30
CN107074848A (zh) 2017-08-18
EA031481B1 (ru) 2019-01-31
HRP20181796T1 (hr) 2018-12-28
CR20170112A (es) 2017-05-26
JO3413B1 (ar) 2019-10-20
JP6611799B2 (ja) 2019-11-27
CO2017002714A2 (es) 2017-06-30
WO2016046225A1 (en) 2016-03-31
PH12017500361B1 (en) 2017-07-17
CN107074848B (zh) 2019-11-01
EA201790715A1 (ru) 2017-07-31
MA40580A (fr) 2017-08-02
PE20170502A1 (es) 2017-04-27
PH12017500361A1 (en) 2017-07-17
PL3197892T3 (pl) 2019-05-31
US20180271845A1 (en) 2018-09-27
RS58000B1 (sr) 2019-01-31
SG11201701183YA (en) 2017-04-27
SMT201800513T1 (it) 2018-11-09
US20170290817A1 (en) 2017-10-12
AR101994A1 (es) 2017-01-25
TW201629056A (zh) 2016-08-16
US10342783B2 (en) 2019-07-09
DK3197892T3 (en) 2018-11-26
MX2017003948A (es) 2017-06-26
AU2015320858B2 (en) 2018-10-18
UA119181C2 (uk) 2019-05-10
BR112017006251A2 (pt) 2017-12-12
LT3197892T (lt) 2018-12-10
SI3197892T1 (sl) 2018-12-31
IL250592A0 (en) 2017-04-30
MA40580B1 (fr) 2018-09-28
KR20170055489A (ko) 2017-05-19
HUE041827T2 (hu) 2019-05-28
CY1121071T1 (el) 2019-12-11
EP3197892A1 (en) 2017-08-02
AU2015320858A1 (en) 2017-03-09
PT3197892T (pt) 2018-12-12
EP3428167A1 (en) 2019-01-16
JP2017528507A (ja) 2017-09-28
ES2690748T3 (es) 2018-11-22
US9956209B2 (en) 2018-05-01
GB201417002D0 (en) 2014-11-12
EP3197892B1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
KR101998000B1 (ko) 신규한 화합물
EP3197893B1 (en) Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
KR20180127979A (ko) 화합물 (s)-4-((s)-3-플루오로-3-(2-(5,6,7,8-테트라히드로-1,8-나프티리딘-2-일)에틸)피롤리딘-1-일)-3-(3-(2-메톡시에톡시)페닐) 부탄산의 시트레이트 염
KR20170053638A (ko) 예를 들면 섬유화 질환의 치료를 위한 알파 v 베타 6 인테그린 길항제로서 나프티리딘 유도체
KR20170054413A (ko) 신규한 화합물
JP2019509305A (ja) インテグリンアンタゴニストとしてのナフチリジン
HK1234041B (en) Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
HK1234041A1 (en) Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220703

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220703

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000